Dear All, How do you ascribe a value to BOTA? It's difficult when you don't know what proportion of sale price BOTA will keep when a pack of laninamivir is sold to distributors in the USA/Western world. What proportion would go to Daiichi-Sankyo (DS) and to other parties (e.g. Hovione)? I suspect the uncertainty about this issue is a problem for the share price on NASDAQ as astute investors who seek to calculate value cannot do so. The royalty share, particularly with DS, needs to be clarified. But if I were DS I might refuse to engage on this point, to keep BOTA in limbo; that could serve DS's interest from a take-over perspective. I would welcome any other thoughts on this issue. Ashmen
BTA Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
